Notably, an increasing number of research studies have indicated that SHP2 inhibitors show efficacy in subsets of RTK-, KRAS-, and BRAF-driven cancers, although it has been previously reported that cancer cells carrying oncogenic RAS/RAF mutations would be refractory to SHP2 inhibition (Chen et al., 2016; Kerr et al., 2021). This evidence concerns the gene KRAS and cancer.